Spatial patterns of structural brain changes in type 2 diabetic patients and their longitudinal progression with intensive control of blood glucose

Diabetes Care

Volumn 38, Issue 1, 2015, Pages 97-104

  Erus, Guray ^a   Battapady, Harsha ^a   Zhang, Tianhao ^a   Lovato, James ^b   Miller, Michael E ^b   Williamson, Jeff D ^c   Launer, Lenore J ^d   Bryan, R Nick ^a   Davatzikos, Christos ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST BAPTIST HEALTH   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BRAIN DISEASE; BRAIN RADIOGRAPHY; BRAIN REGION; BRAIN SIZE; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; FRONTAL LOBE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; INTENSIVE CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL (TOPIC); TEMPORAL LOBE; TREATMENT RESPONSE; WHITE MATTER; BODY MASS; BRAIN; CARDIOVASCULAR DISEASE; GLUCOSE BLOOD LEVEL; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; NEUROIMAGING; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; BRAIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LINEAR MODELS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROIMAGING; RISK FACTORS; TIME FACTORS;

EID: 84920054830     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1196     Document Type: Article

References (45)

1. Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen WH. Ageing and diabetes: Implications for brain function. Eur J Pharmacol 2002; 441:1-14
2. Allen KV, Frier BM, Strachan MW. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 2004;490:169-175
3. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol 2006;5:64-74
4. Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002;1:13-21
5. Launer LJ. Diabetes: vascular or neurodegenerative: An epidemiologic perspective. Stroke 2009;40(3 Suppl.):S53-S55
6. van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ. Brain imaging in patients with diabetes: A systematic review. Diabetes Care 2006;29:2539-2548
7. Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whitmer RA. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: Towards targeted interventions. Lancet Diabetes Endocrinol 2014;2:246-255
8. Moran C, Phan TG, Chen J, et al. Brain atrophy in type 2 diabetes: Regional distribution and influence on cognition. Diabetes Care 2013;36: 4036-4042
9. Brundel M, van den Heuvel M, de Bresser J, Kappelle LJ, Biessels GJ; Utrecht Diabetic Encephalopathy Study Group. Cerebral cortical thickness in patients with type 2 diabetes. J Neurol Sci 2010;299:126-130
10. Brundel M, Kappelle LJ, Biessels GJ. Brain imaging in type 2 diabetes. Eur Neuropsychopharmacol. 15 Mar 2014
11. Buse JB, Bigger JT, Byington RP, et al.; ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods. Am J Cardiol 2007;99:21i-33i
12. Williamson JD, Miller ME, Bryan RN, et al.; ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): Rationale, design, and methods. Am J Cardiol 2007;99:112i-122i
13. Cukierman-Yaffe T, Gerstein HC, Williamson JD, et al.; Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Investigators. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: The Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial. Diabetes Care 2009;32:221-226
14. Launer LJ, Miller ME, Williamson JD, et al.; ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): A randomised open-label substudy. Lancet Neurol 2011;10:969-977
15. Davatzikos C, Genc A, Xu D, Resnick SM. Voxel-based morphometry using the RAVENS maps: methods and validation using simulated longitudinal atrophy. Neuroimage 2001;14: 1361-1369
16. Goldszal AF, Davatzikos C, Pham DL, Yan MX, Bryan RN, Resnick SM. An image-processing system for qualitative and quantitative volumetric analysis of brain images. J Comput Assist Tomogr 1998;22:827-837
17. Shen D, Davatzikos C. Very high-resolution morphometry using mass-preserving deformations and HAMMER elastic registration. Neuroimage 2003;18:28-41
18. Zhang T, Davatzikos C. ODVBA: optimallydiscriminative voxel-based analysis. IEEE Trans Med Imaging 2011;30:1441-1454
19. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998;17:87-97
20. Pham DL, Prince JL. Adaptive fuzzy segmentation of magnetic resonance images. IEEE Trans Med Imaging 1999;18:737-752
21. Shen D, Davatzikos C. HAMMER: hierarchical attribute matching mechanism for elastic registration. IEEE Trans Med Imaging 2002;21: 1421-1439
22. Kabani NJ, Collins DL, Evans AC. A 3D neuroanatomical atlas. Fourth International Conference on Functional Mapping of the Human Brain, 7-12 June 1998,Montreal,Quebec, Canada
23. Resnick SM, PhamDL, KrautMA, Zonderman AB, Davatzikos C. Longitudinal magnetic resonance imaging studies of older adults: A shrinking brain. J Neurosc 2003;23:3295-2301
24. Storey JD. A direct approach to false discovery rates. J Roy Stat Soc B Met 2002;64:479-498
25. Zhang T,Davatzikos C.Optimally-discriminative voxel-based morphometry significantly increases the ability to detect group differences in schizophrenia, mild cognitive impairment, and Alzheimer's disease. Neuroimage 2013;79: 94-110
26. Zhang T, Satterthwaite TD, Elliott M, Gur RC, Gur RE, Davatzikos C. Multivariate fMRI analysis using optimally-discriminative voxelbased analysis. Paper presented at the IEEE International workshop on Pattern Recognition in NeuroImaging, 2-4 July 2012, London, U.K.
27. Gelman A, Park DK. Splitting a predictor at the upper quarter or third and the lower quarter or third. Am Stat 2009;63:1-8
28. Akisaki T, Sakurai T, Takata T, et al. Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese Elderly Diabetes Intervention Trial (J-EDIT). Diabetes Metab Res Rev 2006;22:376-384
29. Manschot SM, Biessels GJ, de Valk H, et al.; Utrecht Diabetic Encephalopathy Study Group. Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia 2007;50:2388-2397
30. Musen G, Lyoo IK, Sparks CR, et al. Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes 2006;55:326-333
31. Samaras K, Lutgers H, Wen W, et al. Glucose disorders exert a detrimental effect on total brain volume in the elderly: A 2-year prospective MRI study. Endocrine Abstracts 2012;29:OC3.6
32. Samaras K, Lutgers HL, Kochan NA, et al. The impact of glucose disorders on cognition and brain volumes in the elderly: The Sydney Memory and Ageing Study. Age (Dordr) 2014;36: 977-993
33. Seaquist ER. The final frontier: how does diabetes affect the brain? Diabetes 2010;59:4-5
34. Tiehuis AM, van der Graaf Y, Visseren FL, et al.; SMART Study Group. Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke 2008;39:1600-1603
35. van Elderen SG, de Roos A, de Craen AJ, et al. Progression of brain atrophy and cognitive decline in diabetes mellitus: A 3-year follow-up. Neurology 2010;75:997-1002
36. Wessels AM, Simsek S, Remijnse PL, et al. Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia 2006;49:2474-2480
37. Lee JH, Yoon S, Renshaw PF, et al. Morphometric changes in lateral ventricles of patients with recent-onset type 2 diabetes mellitus. PLoS ONE 2013;8:e60515
38. Carmichael OT, Kuller LH, Lopez OL, et al., Acceleration of cerebral ventricular expansion in the Cardiovascular Health Study. Neurobiol Aging 2007;28:1316-1321
39. Barzotti T, Gargiulo A, Marotta MG, et al. Correlation between cognitive impairment and the Rey auditory-verbal learning test in a population with Alzheimer disease. Arch Gerontol Geriatr Suppl 2004:57-62
40. Kuslansky G, Katz M, Verghese J, et al. Detecting dementia with the Hopkins Verbal Learning Test and the Mini-Mental State Examination. Arch Clin Neuropsychol 2004;19:89-104
41. Toth C, Schmidt AM, Tuor UI, et al. Diabetes, leukoencephalopathy and RAGE. Neurobiol Dis 2006;23:445-461
42. Enhamre E, Carlsson A, Gr önbladh A, Watanabe H, Hallberg M, Nyberg F. The expression of growth hormone receptor gene transcript in the prefrontal cortex is affected in male mice with diabetes-induced learning impairments. Neurosci Lett 2012;523:82-86
43. Lee JH, Choi Y, Jun C, et al. Neurocognitive changes and their neural correlates in patients with type 2 diabetes mellitus. Endocrinol Metab (Seoul) 2014;29:112-121
44. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: Implications for treatment. CNS Drugs 2003;17:27-45
45. Schiöth HB, Craft S, Brooks SJ, FreyWH 2nd, Benedict C. Brain insulin signaling and Alzheimer's disease: Current evidence and future directions. Mol Neurobiol 2012;46:4-10